Market Capitalization

Browser innovator Shift renews its $25K Impact Grant, fueling sustainable startups as the tech industry grapples with its growing environmental footprint.

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

With a $1.25 billion investment from Apollo Funds, McKesson is spinning off its medical supply unit. Is this a cure for corporate bloat or a new symptom of financialization in healthcare?

QuickLogic's inclusion in the Russell 2000 is a major milestone, but a deeper look reveals a story of high-stakes tech, steep valuation, and intense competition.

A documentary on a punk band of learning-disabled musicians reveals a deeper truth about the infrastructure of empowerment and the untapped human capital in our society.

A Seoul-based AI firm, backed by giants, is set to tackle Southeast Asia's multilingual complexity. This is the story of how AI is becoming the new lingua franca for trade.

Houston-based Cap Six's appointment of veteran Eric Javidi signals an aggressive push to scale, blending seasoned expertise with a tech-driven platform.

Charles Anderson analyzes CorVel's CEO transition, examining how Sarah Scott's deep institutional knowledge, coupled with Michael G. Combs' ongoing strategic role, positions the company for sustained, tech-driven market leadership and operational excellence.

Royce Small-Cap Trust's latest distribution offers more than just income. We break down the fund's consistent performance, tax implications, and what it signals.

The Singaporean firm regained Nasdaq compliance but faces a strict one-year monitoring period, betting its future on key sustainable infrastructure projects.

Facing a severe cash crunch, Jasper Therapeutics is exploring a sale or even a shutdown, placing the future of its promising urticaria drug, briquilimab, in limbo.

A new report reveals a seismic shift in B2B software procurement, where AI search visibility now trumps market share, forcing industry giants to rethink their strategies or risk becoming invisible.

Gold Strategy Inc.'s CAD 2.4M investment from its own top shareholder has been terminated, raising serious questions amid a "Going Concern" warning.

With a fresh $135M in funding, XCENA is scaling its computational memory tech to tackle the data bottlenecks slowing down the entire AI industry.

Zhongchao Inc. seeks $5M in a 'best efforts' deal, but the move sends its stock plummeting over 50% as investors weigh dilution and delisting risks.

Tamboran Resources completes a major acquisition, becoming the top player in the Beetaloo Basin. But can it overcome financial, social, and environmental hurdles?

The newly public juice company plans to leverage its proprietary cold chain tech and recent Walmart expansion to win over investors at a key conference.

BeOne Medicines' immunotherapy TEVIMBRA gains key reimbursement nods, paving the way for Canada's first funded option for a rare head and neck cancer.

A Tulsa jury found a doctor negligent, awarding $15M to a girl left with severe brain damage after a missed diagnosis of bacterial meningitis as an infant.

Groundbreaking research on new drug classes, the gut-brain axis, and personalized medicine will be unveiled at the upcoming American Headache Society meeting.